Immunomodulatory agents changing the landscape of multiple myeloma treatment

被引：3
作者：
Niesvizky, Ruben [1 ]
机构：
[1] New York Presbyterian Hosp, Dept Med, Div Hematol Oncol, Ctr Excellence Lymphoma & Myeloma,Weill Cornell M, New York, NY 10021 USA
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2013年 / 88卷
关键词：
LENALIDOMIDE PLUS DEXAMETHASONE; PERIPHERAL NEUROPATHY; COMBINATION THERAPY; THALIDOMIDE ANALOGS; POMALIDOMIDE; SURVIVAL; CELLS;
D O I：
10.1016/j.critrevonc.2012.12.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S1 / S4
页数：4
相关论文
共 46 条
  • [1] Multiple Myeloma: A Paradigm for Translation of the Cancer Stem Cell Hypothesis
    Agarwal, Jasmin Roya
    Matsui, William
    [J]. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2010, 10 (02) : 116 - 120
  • [2] [Anonymous], HAEMATOLOGICA S1
  • [3] [Anonymous], HAEMATOLOGICA S2
  • [4] [Anonymous], HAEMATOLOGICA
  • [5] [Anonymous], NEW ENGLAND J MED
  • [6] [Anonymous], HAEMATOLOGICA S2
  • [7] [Anonymous], HAEMATOLOGICA S1
  • [8] [Anonymous], NEW ENGLAND J MED
  • [9] Lenalidomide for the treatment of B-cell malignancies
    Chanan-Khan, Asher A.
    Cheson, Bruce D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (09) : 1544 - 1552
  • [10] Corral LG, 1999, J IMMUNOL, V163, P380
12345